newsCOVAX to purchase up to 40 million COVID-19 vaccine doses from Pfizer and BioNTech26 January 2021 | By Hannah Balfour (European Pharmaceutical Review)Through COVAX, doses of the Pfizer-BioNTech vaccine will be provided at a not-for-profit price for 92 low- and lower-middle-income countries.
newsFirst patient dosed with Pfizer’s potential COVID-19 vaccine in US6 May 2020 | By Victoria Rees (European Pharmaceutical Review)Pfizer and BioNTech have initiated Phase I/II trials in the US to determine the safety and optimal dose of four mRNA COVID-19 vaccine candidates.
newsGermany to begin first clinical trial of COVID-19 vaccine candidate23 April 2020 | By Victoria Rees (European Pharmaceutical Review)A Phase I/II clinical trial for BioNTech's BNT162 vaccine programme to prevent COVID-19 infection has been granted approval in Germany.
articleCOVID-19 and big pharma: what are 15 leading companies doing to develop a coronavirus vaccine?10 April 2020 | By Victoria Rees (European Pharmaceutical Review)A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
